Bristol Myers Squibb BMY announced that the FDA has approved a label expansion of its oncology drug Krazati (adagrasib). The FDA granted accelerated approval to Krazati, in combination with Erbitux (...
Source LinkBristol Myers Squibb BMY announced that the FDA has approved a label expansion of its oncology drug Krazati (adagrasib). The FDA granted accelerated approval to Krazati, in combination with Erbitux (...
Source Link
Comments